Crosspoint Capital Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Crosspoint Capital Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-2,514	Closed	-$265K	–	1009
2015 Q3	$265K	Sell	2,514 -509	-17%	-$68K	0.31%	81
2015 Q2	$413K	Buy	3,023 +722	+31%	+$89.5K	0.12%	109
2015 Q1	$287K	Buy	2,301 +143	+7%	+$15.2K	0.14%	113
2014 Q4	$195K	Buy	+2,158	New	+$179K	0.07%	194

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Crosspoint Capital Strategies's BMRN Position: Q4 2015 in Review

Crosspoint Capital Strategies sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2015, closing a stake of 2,514 shares — an estimated $265K sold.

Crosspoint Capital Strategies first reported a position in BMRN in Q4 2014 and held it in 4 quarters. The position peaked at $413K in Q2 2015. 388 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

Crosspoint Capital Strategies reported no remaining BioMarin Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Crosspoint Capital Strategies sold 2,514 BioMarin Pharmaceuticals shares in Q4 2015, an estimated $265K.
Crosspoint Capital Strategies first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 4 quarters.
Crosspoint Capital Strategies's BioMarin Pharmaceuticals position peaked at $413K in Q2 2015.
388 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2015, filed 16 Feb 2016.